纳武利尤单抗联合化疗用于EGFR突变转移性非小细胞肺癌经EGFR酪氨酸激酶抑制剂进展后的治疗:CheckMate 722最终结果
III期CheckMate 722试验将294例EGFR突变转移性NSCLC经EGFR TKI进展后患者随机分配至纳武利尤单抗联合铂双药化疗组或单纯铂双药化疗组。最终分析(中位随访38.1个月)显示,联合组与化疗组中位PFS分别为5.6个月和5.4个月(HR 0.75,95%CI 0.56-1.00,P=0.0528),无显著改善;未发现新的安全性信号。
要点
- 纳武利尤单抗联合化疗较单纯化疗未显著改善PFS(中位5.6 vs 5.4个月,HR 0.75,P=0.0528)。
- 事后亚组分析显示,在携带致敏EGFR突变或既往仅一线EGFR TKI治疗的患者中,联合组PFS有获益趋势。
- 联合组3/4级治疗相关不良事件发生率为44.7%,化疗组为29.4%。
核心结论
- 在既往接受EGFR TKI治疗的EGFR突变转移性NSCLC患者中,纳武利尤单抗联合化疗较单纯化疗未显著改善PFS。
- 未发现新的安全性信号。
研究设计与样本
- III期CheckMate 722试验(ClinicalTrials.gov标识符NCT02864251),评估纳武利尤单抗联合化疗对比化疗。
- 纳入经第一代或第二代EGFR TKI治疗(无EGFR T790M突变)或奥希替尼治疗(伴或不伴T790M突变)后疾病进展的患者。
- 患者按1:1随机分配至纳武利尤单抗(360 mg,每3周一次)联合铂双药化疗(每3周一次)组或单纯铂双药化疗(每3周一次)组,共4个周期。
- 共294例患者被随机分配。
- 主要终点为无进展生存期(PFS);次要终点包括9个月和12个月PFS率、总生存期(OS)、客观缓解率(ORR)和缓解持续时间(DOR)。
主要发现
- 最终分析时中位随访38.1个月,联合组与化疗组中位PFS分别为5.6个月和5.4个月(HR 0.75,95%CI 0.56-1.00,P=0.0528),无显著改善。
- 9个月PFS率联合组为25.9%,化疗组为19.8%;12个月PFS率联合组为21.2%,化疗组为15.9%。
- 事后PFS亚组分析显示,在携带致敏EGFR突变的患者中(HR 0.72,95%CI 0.54-0.97)、既往仅一线EGFR TKI治疗的患者中(HR 0.72,95%CI 0.54-0.97)或两者兼备的患者中(HR 0.64,95%CI 0.47-0.88),联合组有获益趋势。
- 联合组与化疗组中位OS分别为19.4个月和15.9个月。
- 联合组与化疗组ORR分别为31.3%和26.7%,中位DOR分别为6.7个月和5.6个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS: Patients with disease progression after first- or second-generation EGFR TKI therapy (without EGFR T790M mutation) or osimertinib (with/without T790M mutation) were randomly assigned 1:1 to nivolumab (360 mg once every 3 weeks) plus platinum-doublet chemotherapy (once every 3 weeks) or platinum-doublet chemotherapy alone (once every 3 weeks) for four cycles. Primary end point was progression-free survival (PFS). Secondary end points included 9- and 12-month PFS rates, overall survival (OS), objective response rate (ORR), and duration of response (DOR). RESULTS: Overall, 294 patients were randomly assigned. At final analysis (median follow-up, 38.1 months), PFS was not significantly improved with nivolumab plus chemotherapy versus chemotherapy (median, 5.6 v 5.4 months; hazard ratio [HR], 0.75 [95% CI, 0.56 to 1.00]; P = .0528), with 9- and 12-month PFS rates of 25.9% versus 19.8%, and 21.2% versus 15.9%, respectively. Post hoc PFS subgroup analyses showed a trend favoring nivolumab plus chemotherapy in patients with tumors harboring sensitizing EGFR mutations (HR, 0.72 [95% CI, 0.54 to 0.97]), one line of previous EGFR TKI (0.72 [95% CI, 0.54 to 0.97]), or both (0.64 [95% CI, 0.47 to 0.88]). Median OS was 19.4 months with nivolumab plus chemotherapy versus 15.9 months with chemotherapy, while ORR was 31.3% versus 26.7%, and median DOR was 6.7 versus 5.6 months, respectively. Grade 3/4 treatment-related adverse events occurred in 44.7% and 29.4% of patients treated with nivolumab plus chemotherapy and chemotherapy alone, respectively. CONCLUSION: Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.
引用
- Mok T, Nakagawa K, Park K, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024. PMID: 38252907. doi:10.1200/JCO.23.01017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。